Valuation: Talphera, Inc.

Market Cap 73.18M 63.35M 59.21M 54.12M 102M 6.98B 104M 694M 272M 3.49B 275M 269M 11.63B P/E 2026 *
-5.64x
P/E 2027 * -5.04x
Enterprise Value 73.18M 63.35M 59.21M 54.12M 102M 6.98B 104M 694M 272M 3.49B 275M 269M 11.63B EV / Sales 2026 *
-
EV / Sales 2027 * 366x
Free-Float
78.58%
Yield 2026 *
-
Yield 2027 * -
1 day-0.35%
1 week+3.68%
Current month+10.16%
1 month-0.70%
3 months+62.54%
6 months+73.50%
Current year+23.68%
1 week 1.35
Extreme 1.35
1.47
1 month 1.22
Extreme 1.22
1.47
Current year 0.69
Extreme 0.6866
1.5
1 year 0.4
Extreme 0.3974
1.57
3 years 0.38
Extreme 0.38
1.61
5 years 0.38
Extreme 0.38
24.4
10 years 0.38
Extreme 0.38
115
Manager TitleAgeSince
Chief Executive Officer 58 06/03/2017
Director of Finance/CFO 56 01/08/2017
Chief Tech/Sci/R&D Officer - 01/10/2024
Director TitleAgeSince
Director/Board Member 60 01/08/2006
Director/Board Member 72 01/02/2010
Chairman 75 11/02/2013
Date Insider Type Main position Quantity % Market Cap.
4/2/26 A Tax

Chief Technology Officer

2,118 0.0042%
2/12/26 A Buy

Chief Technology Officer

240,000 0.5149%
2/10/26 A Tax

Chief Technology Officer

238,127 0.5109%
Change 5-day change 1-year change 3-year change Capi.($)
-0.35%+3.68%+235.71%+60.21% 73.18M
-0.62%+1.63%+62.55%+21.08% 323B
-2.30%-3.93%+30.19%-13.90% 72.07B
+1.14%+24.83%+65.21%+137.49% 11.65B
+0.63%+1.87%-3.74%-3.95% 8.44B
+3.86%+13.14%-10.94%-11.03% 4.9B
-0.47%+24.45%+3.76%+50.57% 4.36B
+1.74%+11.41%-26.79%+12.70% 4.31B
+1.54%+11.31%+18.66%+50.96% 2.74B
+0.80%+0.63%+1.98%-0.53% 2.27B
Average +0.59%+296.12%+37.66%+30.36% 43.38B
Weighted average by Cap. -0.73%+171.93%+53.08%+17.84%

Financials

2026 *2027 *
Net sales - 200K 173K 162K 148K 279K 19.07M 283K 1.9M 745K 9.54M 751K 735K 31.78M
Net income -17.96M -15.55M -14.54M -13.29M -25.04M -1.71B -25.43M -170M -66.89M -857M -67.46M -65.98M -2.85B -20.15M -17.44M -16.3M -14.9M -28.07M -1.92B -28.51M -191M -75.01M -961M -75.64M -73.99M -3.2B
Net Debt - -
Logo Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of therapies for use in medically supervised settings. The Company’s portfolio consists of nafamostat product candidates and pre-filled syringe product candidates. The Company’s lead product candidate, Niyad, is a lyophilized formulation of nafamostat and is being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit. Niyad is used in adult patients undergoing continuous renal replacement therapy (CRRT). LTX-608 is its nafamostat formulation for direct IV infusion being explored as an investigational product for one or more indications, including antiviral treatment, or treatment of acute respiratory distress syndrome (ARDS) disseminated intravascular coagulation (DIC), or acute pancreatitis. The Company’s two ready-to-use pre-filled syringe (PFS) product candidates include Fedsyra and phenylephrine.
Employees
12
Date Price Change Volume
11/08/26 $1.410 0.00% 30,303
10/08/26 $1.410 -1.40% 95,599
07/08/26 $1.430 0.00% 199,632
06/08/26 $1.430 +5.93% 343,491
05/08/26 $1.350 -0.74% 170,299
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.410USD
Average target price
3.167USD
Spread / Average Target
+124.59%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TLPH Stock